Piper Sandler’s new Neutral rating on Thermo Fisher Scientific (TMO), alongside a Material Transfer Agreement with Polymer Factory Sweden AB, has drawn fresh attention to how the stock reflects industry conditions and emerging technology partnerships.
See our latest analysis for Thermo Fisher Scientific.
Thermo Fisher Scientific’s latest share price of $472.63 sits against a mixed backdrop, with the stock down 20.23% on a year to date share price basis but delivering a 21.55% total shareholder return over the past year, suggesting momentum has cooled recently after a stronger run for investors.
If you are looking for other opportunities tied to scientific tools and advanced measurement, it may be worth scanning for companies at the intersection of healthcare and AI using the 40 healthcare AI stocks
With Thermo Fisher Scientific stock down 20.23% year to date but still showing a 21.55% total return over the past year, the key question is whether recent weakness points to value or if markets are already pricing in future growth.
Most Popular Narrative: 22.7% Undervalued
Thermo Fisher Scientific stock closed at $472.63 compared with a widely followed narrative fair value of $611.56, which frames the current pullback against a higher long term earnings and cash flow story.
The company's positioning as a trusted, end to end partner for pharma and biotech enables greater customer stickiness and deeper integration into high growth markets like clinical research, outsourcing (CDMO), and lab services, enhancing recurring revenue streams and supporting high single digit earnings growth over time. Proactive cost management, leveraging the PPI Business System and AI driven process improvements, is expected to continue expanding operating margins even in a muted demand environment, setting up for stronger net margin expansion as topline growth rebounds.
Want to see what underpins that valuation gap? The narrative leans on steady revenue compounding, firmer margins, and a future earnings profile that assumes disciplined capital return and a richer profit mix.
Result: Fair Value of $611.56 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Thermo Fisher Scientific’s story still depends on tighter academic and government funding, as well as ongoing China weakness, improving rather than putting lasting pressure on demand and margins.
Find out about the key risks to this Thermo Fisher Scientific narrative.
Another View on Thermo Fisher Scientific Stock
While the analyst narrative points to Thermo Fisher Scientific being 22.7% undervalued versus a $611.56 fair value, the current P/E of 25.6x sits almost exactly in line with a fair ratio of 25.5x. At the same time, the stock trades at a clear discount to the Global Life Sciences industry on 34.9x and peers on 40.2x. This suggests less margin of safety if sector sentiment turns, but also less optimism priced in if earnings keep compounding. Which side of that trade off do you think matters more at $472.63?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals around Thermo Fisher Scientific, do you feel the balance of risks and rewards is being priced fairly, or not yet? Take a closer look at both sides of the story and weigh the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Thermo Fisher Scientific?
If you stop at Thermo Fisher Scientific, you could miss other stocks that fit your goals, so give yourself options by scanning a broader set of ideas.
- Spot potential bargains early by checking companies that screen well on quality and valuation using the screener containing 20 high quality undiscovered gems.
- Prioritise resilience by focusing on businesses with robust finances through the solid balance sheet and fundamentals stocks screener (48 results).
- Strengthen your income stream by reviewing companies that pass the yield and durability checks in the 9 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com